Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach
Mepolizumab significantly reduced exacerbations and hospitalizations in eosinophilic COPD patients with frequent OCS use. A 69% response rate at one year and sustained benefit in the second year support its role in this difficult-to-treat population.
Authors
- Peter A. Kopac
- Tina Morgan
- Irena Šarc
- Igor Požek
Institutions
- University of Ljubljana (SI)
- University Clinic of Pulmonary and Allergic Diseases Golnik (SI)
Publication Details
- Journal
- Therapeutic Advances in Respiratory Disease
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17534666251414352
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00